Monday, September 22, 2014

Continuum of care to drive future NOVADAQ imaging growth

Continuum of care to drive future NOVADAQ imaging growth

September 9, 2014 by · Leave a Comment 

Tweet NOVADAQ Technologies (NASDAQ:NVDQ; TSX:NDQ), pioneers in fluorescence imaging solutions for the operating room, is now focused on manufacturing and directly marketing and selling imaging solutions for use at multiple points throughout the patient care continuum. “Our continuum of care includes diagnostics that can be performed at outpatient clinics and by primary care physicians, where […]

Feltl starts Tandem Diabetes with strong buy

Feltl starts Tandem Diabetes with strong buy

September 4, 2014 by · Leave a Comment 

Tweet Feltl & Co. has initiated coverage of Tandem Diabetes Care (NASDAQ:TNDM) with a “strong buy” rating and $19 price target. The stock closed at $14.36 on Thursday. “Tandem Diabetes entered the pump market with the t:slim in late 2012 and is gaining traction with both diabetics utilizing multiple daily injections (MDI) to deliver insulin, […]

Alitair gets second U.S. patent on ion exchange resin

Alitair gets second U.S. patent on ion exchange resin

September 4, 2014 by · Leave a Comment 

Tweet Closely-held Alitair Pharmaceuticals has received a second patent from the U.S. Patent and Trademark Office for its ion exchange resin formulation of benzonatate, benzonatate polacrilex. The new patent contains a composition of matter claim, covering the use of Alitair’s ion exchange formulation of benzonatate. The new patent also contains claims for using benzonatate polacrilex […]

Dipexium aims to have first topical antibiotic approved for DFI

Dipexium aims to have first topical antibiotic approved for DFI

September 2, 2014 by · Leave a Comment 

Tweet Dipexium (NASDAQ:DPRX) is enrolling patients in two pivotal Phase 3 trials of its Locilex topical antibiotic in what it hopes will be the first FDA-approved antibiotic topical cream for the treatment of mild infections of diabetic foot ulcers. “Current treatments used off-label to treat mild diabetic foot infections (DFI) generate systemic resistance, exhibit poor […]

Titan implanting treatments for opioid dependence

Titan implanting treatments for opioid dependence

August 19, 2014 by · Leave a Comment 

Tweet In the continuing struggle to circumvent abuse of drugs to treat opioid dependence and enhance compliance regimes for better outcomes, Titan Pharmaceuticals (OTCBB:TTNP) is leading the race with a matchstick-sized implant of the approved drug, buprenorphine, which eases withdrawal symptoms. “With more than two million people in the U.S. suffering from opioid dependence, there […]

Leerink ups Intra-Cellular price target to $35

Leerink ups Intra-Cellular price target to $35

August 13, 2014 by · Leave a Comment 

Tweet Leerink Partners has raised its price target for “outperform-rated” Intra-Cellular Therapies (NASDAQ:ITCI) to $35 from $34 in assumed coverage. The stock closed at $15.98 on Tuesday. Intra-Cellular has announced that following a successful end of Phase 2 meeting with the FDA, it will conduct two pivotal Phase 3 trials with its ITI-007 drug candidate […]

Knight Therapeutics to sell priority review voucher

Knight Therapeutics to sell priority review voucher

August 12, 2014 by · Leave a Comment 

Tweet Knight Therapeutics (TSX:GUD) has entered into an arrangement with a global investment banking firm to sell its tropical disease priority review voucher (PRV). Developed by the FDA in 2007, a PRV is an incentive for companies to invest in new drugs and vaccines for neglected tropical diseases, and since 2012, a similar incentive exists […]

FDA eases Tekmira’s TKM-Ebola to partial clinical hold

FDA eases Tekmira’s TKM-Ebola to partial clinical hold

August 8, 2014 by · Leave a Comment 

Tweet The FDA has verbally confirmed that it has modified a full clinical hold on Tekmira Pharmaceuticals’ (NASDAQ:TKMR; TSX:TKM) TKM-Ebola Investigational New Drug application to a partial clinical hold. “We view this news as extremely positive, as this paves the way for TKM-Ebola to potentially be used in the treatment of individuals currently infected with […]

In conversation with Jason Mitakidis

In conversation with Jason Mitakidis

August 5, 2014 by · Leave a Comment 

Tweet As president and CEO of closely held Cyclica, Jason Mitakidis first became interested in computer simulation or, in silico, drug discovery while he was working as a bioinformatician at the Barcode of Life Project in 2006 and 2007. Prior to co-founding Cyclica in 2011, he gained several years of research experience in the fields […]

Clarus starts Tekmira Pharma at buy

Clarus starts Tekmira Pharma at buy

July 31, 2014 by · Leave a Comment 

Tweet Clarus Securities has initiated coverage of Tekmira Pharmaceuticals (NASDAQ:TKMR; TSX:TKM) with a “buy” rating and price target of $22.50, saying the company is delivering multiple paths to value. The stock closed at $12.73 on Wednesday. Tekmira is focused on RNA interference (RNAi) therapeutics and is a global leader in the field. The company develops […]

Next Page »

Email Newsletters with Constant Contact
Google+